CN100422322C - 口蹄疫病毒疫苗 - Google Patents

口蹄疫病毒疫苗 Download PDF

Info

Publication number
CN100422322C
CN100422322C CNB028129504A CN02812950A CN100422322C CN 100422322 C CN100422322 C CN 100422322C CN B028129504 A CNB028129504 A CN B028129504A CN 02812950 A CN02812950 A CN 02812950A CN 100422322 C CN100422322 C CN 100422322C
Authority
CN
China
Prior art keywords
foot
mouth disease
vaccine
animal
albumen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028129504A
Other languages
English (en)
Chinese (zh)
Other versions
CN1533242A (zh
Inventor
M·J·格鲁布曼
J·钦桑加兰
M·科斯特
M·P·莫雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of CN1533242A publication Critical patent/CN1533242A/zh
Application granted granted Critical
Publication of CN100422322C publication Critical patent/CN100422322C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB028129504A 2001-04-26 2002-04-26 口蹄疫病毒疫苗 Expired - Fee Related CN100422322C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28634501P 2001-04-26 2001-04-26
US60/286,345 2001-04-26
US10/128,463 2002-04-24
US10/128,463 US8058248B2 (en) 2001-04-26 2002-04-24 Foot and mouth disease virus vaccine comprising interferons

Publications (2)

Publication Number Publication Date
CN1533242A CN1533242A (zh) 2004-09-29
CN100422322C true CN100422322C (zh) 2008-10-01

Family

ID=26826603

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028129504A Expired - Fee Related CN100422322C (zh) 2001-04-26 2002-04-26 口蹄疫病毒疫苗

Country Status (13)

Country Link
US (1) US8058248B2 (enExample)
EP (1) EP1389043B1 (enExample)
JP (1) JP2004530677A (enExample)
CN (1) CN100422322C (enExample)
AR (1) AR040623A1 (enExample)
AT (1) ATE437656T1 (enExample)
AU (1) AU2002303503B2 (enExample)
BR (1) BR0209251A (enExample)
CA (1) CA2445266A1 (enExample)
DE (1) DE60233127D1 (enExample)
MX (1) MXPA03009763A (enExample)
NZ (1) NZ529305A (enExample)
WO (1) WO2002087336A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
CN100572541C (zh) * 2007-05-28 2009-12-23 中国农业科学院兰州兽医研究所 口蹄疫病毒双效疫苗载体、其制备方法及应用
WO2011091027A2 (en) * 2010-01-19 2011-07-28 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant live attenuated foot-and-mouth disease (fmd) vaccine containing mutations in the l protein coding region
CN104774856B (zh) * 2011-04-25 2017-12-08 中国农业科学院兰州兽医研究所 对口蹄疫病毒有抑制作用的干扰靶序列
GB201111183D0 (en) * 2011-06-30 2011-08-17 Animal Health Inst Peptide
CN102988970B (zh) * 2011-09-19 2014-06-18 内蒙古必威安泰生物科技有限公司 口蹄疫纯化疫苗及其制备方法和应用
CN102363043B (zh) * 2011-10-09 2013-05-01 中国农业科学院兰州兽医研究所 一种猪用c型口蹄疫基因工程疫苗佐剂及其制备方法
KR101329348B1 (ko) * 2012-05-31 2013-11-15 대한민국 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스
CN103592441B (zh) * 2013-10-29 2015-06-17 王明丽 一种重组猪干扰素ɑ双抗体夹心法免疫胶体金检测试纸条的制备方法
CN106546747B (zh) * 2016-10-31 2019-03-01 江苏众红生物工程创药研究院有限公司 一种干扰素生物学活性的检测方法
CN108103034B (zh) * 2017-12-15 2022-06-24 云南农业大学动物医学院 同时表达A型、O型和Asia-1型口蹄疫病毒VP1基因重组腺病毒、构建方法及应用
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86103718A (zh) * 1985-06-03 1987-02-04 伊莱利利公司 口蹄疫合成疫苗的制备方法
CN1090203A (zh) * 1993-10-21 1994-08-03 复旦大学 家畜口蹄疫病素多肽疫苗及其制备方法
US5672510A (en) * 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1999010516A2 (en) * 1997-08-29 1999-03-04 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
CN1238011A (zh) * 1996-09-18 1999-12-08 拜尔公司 口蹄疫病毒的免疫原性肽

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831023A (en) 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US4795436A (en) 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6221361B1 (en) 1995-01-19 2001-04-24 Syntro Corporation Recombinant swinepox virus
US5612040A (en) * 1995-04-07 1997-03-18 The United States Of America As Represented By The Secretary Of Agriculture Non-infectious foot-and-mouth disease viruses
US5824316A (en) * 1996-05-24 1998-10-20 The United States Of America As Represented By The Secretary Of Agriculture Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines
SK50699A3 (en) * 1996-10-18 2000-05-16 Canji Inc Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
AU1463300A (en) * 1998-11-09 2000-05-29 Nader G. Abraham Retroviral vectors encoding interferon alpha and uses thereof
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86103718A (zh) * 1985-06-03 1987-02-04 伊莱利利公司 口蹄疫合成疫苗的制备方法
US5672510A (en) * 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
CN1090203A (zh) * 1993-10-21 1994-08-03 复旦大学 家畜口蹄疫病素多肽疫苗及其制备方法
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
CN1238011A (zh) * 1996-09-18 1999-12-08 拜尔公司 口蹄疫病毒的免疫原性肽
WO1999010516A2 (en) * 1997-08-29 1999-03-04 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Also Published As

Publication number Publication date
AR040623A1 (es) 2005-04-13
ATE437656T1 (de) 2009-08-15
NZ529305A (en) 2005-08-26
AU2002303503B2 (en) 2007-09-20
EP1389043A1 (en) 2004-02-18
US20030171314A1 (en) 2003-09-11
EP1389043A4 (en) 2004-09-08
WO2002087336A1 (en) 2002-11-07
MXPA03009763A (es) 2004-07-30
BR0209251A (pt) 2005-02-09
US8058248B2 (en) 2011-11-15
DE60233127D1 (enExample) 2009-09-10
JP2004530677A (ja) 2004-10-07
EP1389043B1 (en) 2009-07-29
CA2445266A1 (en) 2002-11-07
CN1533242A (zh) 2004-09-29

Similar Documents

Publication Publication Date Title
Romero et al. Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease
KR100746524B1 (ko) 재조합 돼지 아데노바이러스 벡터
CN100422322C (zh) 口蹄疫病毒疫苗
Wu et al. Adenovirus-mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus
PL190150B1 (pl) Kompozycja szczepionki przeciwko patogenom psów, zastosowanie jednego albo wielu plazmidów, zestaw do szczepienia, szczepionki dla psów, zastosowanieplazmidu oraz sposób szczepienia
EP0334530B1 (en) A recombinant marek's disease virus and a vaccine
CN100354414C (zh) 一种伪狂犬病gEˉ/gIˉ基因缺失毒株、含有该毒株的灭活疫苗及应用
US4738846A (en) Vaccine for vesicular stomatitis virus
AU732885B2 (en) Canine parvovirus DNA vaccines
AU2002303503A1 (en) Foot and mouth disease virus vaccine
CN117143924B (zh) 共表达猫杯状病毒和猫细小病毒抗原蛋白的重组猫疱疹病毒及其活载体疫苗和应用
Oberg et al. Bacterially expressed nucleoprotein of infectious hematopoietic necrosis virus augments protective immunity induced by the glycoprotein vaccine in fish
US20100047274A1 (en) Inoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alpha-virus-induced encephalitides
JP2024512103A (ja) ワクチンプラットフォームとしての高弱毒化複製可能組換えポックスウイルスおよびその利用方法
WO2006002594A1 (en) A recombinant canine adenovirus type-2 and the preparation method and usage thereof
Gillespie et al. Response of dairy calves to vaccinia viruses that express foreign genes
US20230405110A1 (en) Canine Parvovirus
Caron et al. Granulocyte-macrophage colony-stimulating factor does not increase the potency or efficacy of a foot-and-mouth disease virus subunit vaccine
EP0471457A2 (en) Herpesvirus-based viral vector which expresses a foot & mouth disease virus epitope
Kieny et al. Development of animal recombinant DNA vaccine and its efficacy in foxes
EP0863151A1 (en) "Canine parvovirus dna vaccines"
Grubman et al. Novel Viral Disease Control Strategy
Yilma Genetically engineered vaccines
Yilma A recombinant vaccine for rinderpest

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081001

Termination date: 20100426